Rodent data and general hypothesis: Antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone

Journal of Neural Transmission

Volumn 105, Issue 4-5, 1998, Pages 365-396

  Martin, P ^a,d   Waters, N ^a   Schmidt, C J ^b,c   Carlsson, A ^a   Carlsson, M L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SANOFI   (France)

^c PFIZER INC   (United States)

^d Box 431 ^*  (Sweden)

Author keywords

Locomotion; M100907; MDL100907; MK 801; Monoaminergic biochemistry; Mouse; Psychosis; Schizophrenia; Serotonin

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 5 HYDROXYTRYPTOPHAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; BRAIN MONOAMINE; CLOZAPINE; DIZOCILPINE; FENCLONINE; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; META ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

3,4-DIHYDROXYPHENYLACETIC ACID; 5-HYDROXYTRYPTOPHAN; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; BRAIN; DEXTROAMPHETAMINE; DIHYDROXYPHENYLALANINE; DIZOCILPINE MALEATE; DOPAMINE; FENCLONINE; FLUOROBENZENES; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICE; MICE, INBRED STRAINS; MODELS, NEUROLOGICAL; MOTOR ACTIVITY; NOREPINEPHRINE; NORMETANEPHRINE; ORGAN SPECIFICITY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0031950519     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050064     Document Type: Article

References (117)

1. Abel KM, O'Keane V, Murray RM (1996) Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br J Psychiatry 168(1): 57-60
2. Abi Dargham A, Lamelle M, Aghajanian GK, Charney D, Krystal J (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9: 1-17
3. Ahlenius, S (1989) Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64(1): 3-5
4. Alarcon RD, Johnson BR, Lucas JP (1991) Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine [see comments]. J Am Acad Child Adolesc Psychiatry 30: 999-1002
5. Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradioeraphic analysis in rat brain. Brain Res Bull 16: 517-525
6. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79: 565-575
7. Arora RC, Meltzer HY (1980) In vitro effect of phencyclidine and other psychomotor stimulants on serotonin uptake in human platelets. Life Sci 27: 1607-1613
8. Arya DK (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors [see comments]. Br J Psychiatry 165: 728-733
9. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent [see comments]. N Engl J Med 324: 746-754
10. Bartfai A, Edman G, Levander SE, Schalling D, Sedvall G (1984) Bilateral skin conductance activity, clinical symptoms and CSF monoamine metabolite levels in unmedicated schizophrenics, differing in rate of habituation. Biol Psychol 18: 201-218
11. Baumann MH, Rutter JJ, Auerbach SB (1993) Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32: 1381-1386
12. Berendsen HH, Broekkamp CL, van Delft AM (1991) Depletion of brain serotonin differently affects behaviors induced by 5HT1A, 5HT1C, and 5HT2 receptor activation in rats. Behav Neural Biol 55: 214-226
13. Bischoff S, Heinrich M, Sonntag JM, Krauss J (1986) The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129: 367-370
14. Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229: 75-82
15. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153: 1625-1627
16. Bunney BG, Bunney WE, Carlsson A (1995) Chapter 101: schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1205-1214
17. Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25: 437-440
18. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221-226
19. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276
20. Carlsson ML (1995) The selective 5-HT2A-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J Neural Transm [Gen Sect] 100: 225-237
21. Carlsson ML, Martin P, Carlsson A (1995) Low doses of the 5-HT2A antagonist MDL100,907 counteract NMDA receptor antagonist-induced, but not d-amphtamine-induced, hyperactivity in mice. Society for Neuroscience, 25th Annual Meeting, San Diego, 21: 745
22. Caroli F, Aymard N, Viala A, Smagghe PO (1995) [Possible combination of clozapine and specific serotonin reuptake inhibitors? (letter)]. Encephale 21: 482-483
23. Casacchia M, Casati C, Fazio C (1975) Letter: p-Chlorophenylalanine in schizophrenia. Biol Psychiatry 10: 109-110
24. Cassady SL, Thaker GK (1992) Addition of fluoxetine to clozapine [letter] [published erratum appears in Am J Psychiatry (1992) 149(11): 1622] [see comments]. Am J Psychiatry 149: 1274
25. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG (1994) Serum concentrations of clozapine and its major metabolites; effects of contreatment with fluoxetine and valproate. Am J Psychiatry 151: 123-125
26. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135-145
27. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology Berl 120: 67-74
28. Crespi F, Garratt JC, Sleight AJ, Marsden CA (1990) In vivo evidence that 5-hydroxytryptamine (5-HT) neuronal firing and release are not necessarily correlated with 5-HT metabolism. Neuroscience 35: 139-144
29. Criswell HE, Johnson KB, Mueller RA, Breese GR (1993) Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J Pharmacol Exp Ther 265: 1001-1010
30. Cuzick J (1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90
31. Dai H, Gebhardt K, Carey RJ (1995) Time course effects of MK-801: the relationship between brain neurochemistry and behavior. Brain Res Bull 36: 175-180
32. DeLisi LE, Freed WJ, Gillin JC, Kleinman JE, Bigelow LB, Wyatt RJ (1982) P-chlorophenylalanine trials in schizophrenic patients. Biol Psychiatry 17: 471-477
33. Dragunow M, Faull RL (1990) MK801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci Lett 113: 144-150
34. Dudley M, Ogden A, Carr A, Nieduzak T, Kehne J (1990) MDL100,907, (+-alfa-(2,3-Dimethoxyphenyl)-1-[2-(4-Fluorophenylethyl)]-4-Piperidinemethanol), a potent, chiral, 5-HT2A-receptor antagonist. Society for Neuroscience, St. Louis, Abstract 427,19
35. Farde L, Nordstrom AL, Nyberg S, Halldin C, Sedvall G (1994) D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55 [Suppl B]: 67-69
36. Fenton WS, Lee B (1993) Can clozapine response be predicted? A naturalistic pilot study. J Nerv Ment Dis 181: 62-64
37. Gattaz WF, Waldmeier P, Beckmann H (1982) CSF monoamine metabolites in schizophrenic patients. Acta Psychiatr Scand 66: 350-360
38. Gerlach J, Lublin H, Peacock L (1996) Extrapyramidal symptoms during long-term treatment with antipsychotics. Special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 14(3S): 35S-39S
39. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology Berl 129: 79-84
40. Graybiel AM, Moratalla R, Robertson HA (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 87: 6912-6916
41. Hansson LO, Waters N, Winblad B, Gottfries CG, Carlsson A (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm [Gen Sect] 98: 217-235
42. Hertel P, Nomikos GG, Schilström B, Arborelius L, Svensson TH (1997) Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha2-adrenoceptor antagonism. Neuropsychopharmacology 17(1): 44-55
43. Hiramatsu M, Cho AK, Nabeshima T (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166: 359-366
44. Hjorth S, Bengtsson HJ, Milano S, Lundberg JF, Sharp T (1995) Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release-I. BMY7378 and prazosin. Neuropharmacology 34(6): 615-620
45. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm [Gen Sect] 89: 1-10
46. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology Berl 120: 128-133
47. Honigfeld G, Patin J (1989) Predictors of response to clozapine therapy. Psychopharmacology Berl 99 [Suppl]: S64-S67
48. Hori T, Suzuki T, Baba A, Abe S, Yamamoto T, Moroji T, Shiraishi H (1996) Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci Lett 209: 153-156
49. Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A (1989) 5-HT1c receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. Naunyn Schmiedebergs Arch Pharmacol 339: 252-258
50. Jackson DM, Johansson C, Lindgren LM, Bengtsson A (1994) Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 48: 465-471
51. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia [see comments]. Am J Psychiatry 148: 1301-1308
52. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993) Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology Berl 112: S90-S94
53. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476
54. Kehne JH, Baron BM, Carr AA, Chancy SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968-981
55. Kennett GA (1993) 5-HT1c receptors and their therapeutic relevance. Curr Opin Invest Drugs 2(4): 317-362
56. Koe BK, Weissman A (1966) pChlorophenylalanine: a specific depleter of brain serotonin. J Pharmacol Exp Ther 154: 499
57. Kopala LC, Good KP, Fredrikson D, Whitehorn D, Lazier L, Honer WG (1997) Risperidone for first episode schizophrenia: symptom response to lower, intermediate and higher dose strategies. Schizophr Res (Abstracts) 24: 194
58. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr., Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214
59. Kuczenski R, Segal DS (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9: 2051-2065
60. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317
61. Kuroki T, Ichikawa J, Dai J, Meltzer HY (1996) R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res 743: 357-361
62. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13(1): 9-19
63. Lauterbach EC (1991) Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia. Clin Neuropharmacol 14: 547-555
64. Lejeune F, Gobert A, Rivet JM, Millan MJ (1994) Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res 656: 427-431
65. Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449-454
66. Lieberman JA, Kane JM, Safferman AZ, Pollack S, Howard A, Szymanski S, Masiar SJ, Kronig MH, Cooper T, Novacenko H (1994) Predictors of response to clozapine. J Clin Psychiatry 55 [Suppl B]: 126-128
67. Löscher W, Hönack D (1992) The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215: 199-208
68. Löscher W, Annies R, Hönack D (1991) The N-methyl-D-aspartale receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128(2): 191-194
69. Löscher W, Annies R, Hönack D (1993) Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 242: 263-274
70. Lucki I, Ward HR, Frazer A (1989) Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249(1): 155-164
71. Maj J, Rogoz Z, Skuza G (1991) Locomotor hyperactivity induced by MK-801 in rats. Pol J Pharmacol Pharm 43: 449-458
72. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307
73. Mandalos GE, Szarek BL (1990) Dose-related paranoid reaction associated with fluoxetine. J Nerv Ment Dis 178: 57-58
74. Markstein R, Gull P, Rüedeberg C, Urwyler S, Jalon AL, McAllister K, Dixon AK, Hoyer D (1996) SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J Neural Transm [Gen Sect] 103: 261-276
75. Martin P, Svensson A, Carlsson A, Carlsson ML (1994) On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801. J Neural Transm [Gen Sect] 95: 113-121
76. Martin P, Waters NW, Holm S, Carlsson A, Carlsson ML (1995) The stimulation of forward locomotion elicited by MK-801 is abolished by low doses of the 5-HT2a receptor antagonist MDL100,907. Society for Neuroscience, 25th Annual Meeting, San Diego, 21: 2057
77. Martin P, Waters NW, Waters ES, Carlsson A, Carlsson ML (1997a) MK-801 hyperlocomotion: differential effects of MDL100907, SDZ PSD-958 and raclopride. Eur J Pharmacol 335: 107-116
78. Martin P, Waters N, Carlsson A, Carlsson ML (1997b) The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104: 561-564
79. Martin P, Waters NW, Waters ES, Carlsson A, Carlsson ML (1997c) The inhibitory effect of MDL100,907 on MK-801-induced hyperlocomotion is markedly counteracted by ritanserin. Soc Neurosci Abstr 23 (Part 1): 802
80. Mathé JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309: 1-11
81. Maurel Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280: R9-R11
82. Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114: 9-23
83. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology Berl 99 [Suppl]: S68-S72
84. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin, pK, values. J Pharmacol Exp Ther 251: 238-246
85. Minabe Y, Emori K, Ashby CR Jr (1996) The depletion of brain serotonin levels by parachlorophenylalanine administration significantly alters the activity of midbrain dopamine cells in rats: an extracellular single cell recording study. Synapse 22: 46-53
86. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551
87. Moser PC, Moran PM, Frank RA, Kehne JH (1996) Reversal of amphetamine-induced behaviours by MDL100,907, a selective 5-HT2A antagonist. Behav Brain Res 73: 163-167
88. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513
89. Ögren SO, Goldstein M (1994) Phencyclidine-and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11: 167-177
90. Owen RR, Gutierrezesteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, Murphy DL, Pickar D (1993) Effects of clozapine and fluphenazine treatment on responses to M-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50: 636-644
91. Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260: 1209-1213
92. 3 mediated control of dopaminergic function. Psychopharmacology 112: S60-S67
93. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 49(5): 345-353
94. Pickar D, Owen RR, Jr, Litman RE, Hsiao JK, Su TP (1994) Predictors of clozapine response in schizophrenia. J Clin Psychiatry 55 [Suppl B]: 129-132
95. Ping HX, Xie L, Gong XJ, Liu GQ, Wu HQ (1992) Effect of dizocilpine maleate on monoamines and their metabolites in rat brain. Chung Kuo Yao Li Hsueh Pao 13: 206-208
96. Popova NK, Kulikov AV (1995) On the role of brain serotonin in expression of genetic predisposition to catalepsy in animal models. Am J Med Genet 60: 214-220
97. Rimón R, Roos BE, Räkköläinen V, Alanen Y (1971) The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 15: 375-378
98. Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284: 472-473
99. Schmidt CJ, Fadayel GM (1995) The selective 5-HT2A receptor antagonist, MDL100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273: 273-279
100. Schmidt CJ, Kehne JH, Carr AA, Fadayel GM, Humphreys TM, Kettler HJ, McCloskey TC, Padich RA, Taylor VL, Sorensen SM (1993) Contribution of serotonin neurotoxins to understanding psychiartic disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 8 [Suppl 2]: 25-32
101. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology Berl 124: 57-73
102. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JAr, et al (1995) Ziprasidone (CP-88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113
103. Silver H, Kushnir M, Kaplan A (1996) Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 40(7): 671-674
104. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26: 1435-1439
105. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684-691
106. Stahl SM, Wetz K (1987) Indoleamines and schizophrenia. In: Henn FA, DeLisi LE (eds) Handbook of schizophrenia, vol 2. Neurochemistry and neuropharmacology of schizophrenia. Elsevier, Amsterdam, pp 257-296
107. Svensson A, Pileblad E, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm [Gen Sect] 85: 117-129
108. Svensson K, Johansson AM, Magnusson T, Carlsson A (1986) (+)-AJ 76 (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 334(3): 234-245
109. Szegedi A, Wiesner J, Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine [letter]. J Clin Psychopharmacol 15: 141-143
110. Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T (1993) The dopamine-serotonin relationship in clozapine response. Psychopharmacology 112: S85-S89
111. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology Berl 98: 45-50
112. Waters N, Carlsson A, Hansson L (1994) An animal model of schizophrenia based on multivariate analysis monoaminergic biochemistry and behaviour. Society for Neuroscience, 24th Annual Meeting, Miami Beach, Florida, 20, part 1: 825
113. Waters N, Lundgren C, Hansson LO, Carlsson ML (1996) Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA antagonists D-CPPene and CGS19755. J Neural Transm [GenSect] 103: 117-129
114. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992) MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem 58: 1573-1575
115. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83: 7104-7108
116. Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273: 1063-1070
117. Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44: 401-458